Sun Pharmaceuticals Industries: Good revenue growth due to one off generic sales and strong ROW performance
Good revenue growth due to one off generic sales and strong ROW performance: Net Revenues for the quarter increased by 15.9% YoY to Rs 83.6 bn, above our expectation of Rs 82.6 bn. EBDITA Margins for the quarter decreased from 23.8% to 23.3% YoY.